Avastin for breast cancer is controversial because it does not extend life or its quality and it is expensive. It costs $88,000 per year of treatment. There are conflicts of interest for the oncologists who make a profit from the chemotherapies they sell to their patients. Big pharma is insensitive to what this drug actually does; it is primarily interested in profits for their investors.
Since this program was completed, the FDA disapproved Avastin for treatment of breast cancer. It looks like Dr. Len called this one right long before the FDA corrected itself.
